Shane Neibart, Resident Physician at Harvard Radiation Oncology Program, shared on X:
“More on RT Toxicity:
HYPNO trial published and I will leave it to others for the deep dive.
I wonder if we should interpret the acute toxicity data with caution…
From methods:
Time and severity grading of the early radiation reactions in the mucosa and skin were noted. After treatment, the first scheduled follow-up was about 2 months after the end of therapy to record persistent early toxicities and early tumor response.
Any concerns here?
Kinetics of acute toxicity after (moderately) hypofractionated RT are different from conventional RT. Would we expect to see the full scope of acute toxicity from this schedule?
Practice patterns are likely different (inter)nationally – but some are seeing patients 1-2 weeks post RT for skin check etc. It is very plausible hypofrac is toxicity sparing, but we need to know what happened between RT end and 2 months.”
Title: Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial
Authors: Søren Bentzen, Tejpal Gupta, Alexandre Jacinto, Eduardo Rosenblatt, Suman Bhasker, Misleidy Napoles, Sergio Binia, Yaowalak Chansilpa, Sergio Aguiar, Murugaiyan Nagarajan, Sarbani Laskar, Pedro De Marchi, Olga Goloubeva, Kirsten Hopkins, Eduardo Zubizarreta, Jai Agarwal, May Abdel-Wahab
Read the Full Article.
Other articles featuring Shane Neibart on OncoDaily.